Overview

Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.